Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Mondal, P.
- Management and Rehabilitation of a Sundarban Tiger with a Chronic Wound and Infective Arthritis
Abstract Views :249 |
PDF Views:1
Authors
Affiliations
1 Zoological garden, Alipore, Kolkata-27, IN
1 Zoological garden, Alipore, Kolkata-27, IN
Source
Indian Forester, Vol 139, No 10 (2013), Pagination: 879-882Abstract
Sundarban mangrove is natural habitat of a number of endangered and threatened species including the Bengal tiger. A Sundarban tiger aged about 6-7 years was brought from Sundarban with wound and hind quarter weakness. From haematological, biochemical and radiographic examination it was diagnosed that the tiger was suffering from infective arthritis. After prolonged treatment the animal became healthy and finally released in Sundarban again.Keywords
Sundarban Tiger, Wound, Infective Arthritis
References
- Nigam, P. and Prumamthadathil, C.S. (2011). Critical care and emergency management of wild animals, Intas Polivet, 12(ii): 153-162.
- Grimm, K.A. and Lamont, L.A. (2007). Clinical Pharmacology. In: Zoo Animal and Wildlife Immobilisation and Anesthesia, (G. West, D. Heard and N. Caulkett, edts.), Blackwell Publishing, Iowa 50014, USA, pp- 11-13.
- Bose, S. (2004). The Sundarbans Biosphere: A study on unceratinities and impacts in active delta region. In: Proceedings of 2nd APHW Conference, July 5-8, 2004, Singapore.
- Bennett, D. and Taylor, D.J. (1988). Bacterial infective arthritis in the dog, Journal of Small Animal Practice. 29(4): 207-230
- Denny,H. and Butterworth, S. (2000). A Guide to Canine and Feline Orthopaedic Surgery, Blackwell science, U.K. pp 73-74.
- Kirpensteijn, J. and Haar, G.P. (2013). Reconstructive Surgery and Wound Management of the Dog and Cat, Manson publishing, U.K. pp27- 28.
- Ramanathan, A., Malik, P.K. and Prasad, G. (2007). Seroepizootiological survey for selected viral infections in captive Asiatic lions from western India. Journal of Zoo and Wildlife Medicine, 38(3): 400-408.
- Shrivastav, A.B., Singh, K.P., Mittal, S.K. and Malik, P.K. (2012). Haematological and biochemical studies in tigers. Eur J. Wildl. Res., 58(1):365- 67.
- Sajjad, S., Farooq, U., Malik, H., Anwar, M. and Ahmad, I. (2012). Comparative hematological variables of Bengal tigers (Panthera tigris tigris) kept in Lahore Zoo and Lahore. Turk. J. Vet. Anim. Sci., 36(4): 346-351.
- Bohling, M.W., Henderson, R.A., Swaim, S.F., Kincaid, S.A. and Wright, J.C. (2004). Cutaneous wound healing in the cat: a macroscopic description and comparison with cutaneous wound healingin the dog. Vet Surg., 33(6):579-87.
- Phase-3 Studies of Welchol on Anti-Diabetic Activity
Abstract Views :217 |
PDF Views:2
Authors
Affiliations
1 Bharat Technology, Banitabla, Howrah, W.B, IN
2 Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, IN
1 Bharat Technology, Banitabla, Howrah, W.B, IN
2 Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 3 (2010), Pagination: 211-214Abstract
Diabetes is a condition primarily defined by the level of hyperglycaemia giving rise to risk of macro and micro vascular complication and diminished quality of life. Roman physician Areataeus was introduced the name diabetes in 1st century A.D. Diabetes treatment include a number of drugs either can be used alone or in combination. The present articles concentrate on the phase-3 studies of Welchol as an adjunct to Metformin in type-ll diabetes who are not responding to other combination of anti-diabetic drugs.Keywords
Diabetes, Hyperglycaemia, Complications, Welchol.References
- Finkel.R, Clark,M,A; Cubeddu,L.X; Hervey,R,A; Champe,P.C; Li ppincott's Illustrated review: Pharmacology 4th edition. New Delhi: Wolter Kluwer/Lippincott Williams and Wilkins, pp.285-297.
- Harold E. Bays, MD; Ronald B. Goldberg, MD; Kenneth E. Truitt, MD; Michael R. Jones; Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin. Arch Intern Med.2008; 168(18):pp.1975-1983.
- Goldberg R.B; Fonseca V.A; Truitt K.E; Jones M.R ;Archives of internal medicine: efficacy and safety of Colesevelam in patients with type-2 diabetes mellitus and inadequate glycemic control receiving insulin based therapy, Lipid Disorder Clinic, Division of endocrinology, Diabetes and Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL;2008; 33136, USA.
- Satoshkar R.S, Bhandarkar Sd, Nirmala N.R: Pharmacology and pharmacotherapeutics,12th ed;2007;pp.869-900.
- RXLIST-The interdrug index,july,2008, copyright(c) 2008, First Data Bank.,Inc.
- Staels.B, Kuipers.F; Bile acid sequestrants and the treatment of type-2 diabetes mellitus. Drugs; 2007; 67 (10); pp.1383-92.
- Welchol (Colesevelam hydrochloride) prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc; 2008.
- Denkins DJ, et al. Effect of a low glycemic index or a high cereal fiber diet on type 2 diabetes: A randomized trial. Journal of the American Medical Association. 2008; pp.300:2742
- Sigal RJ, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes. Annals of Internal Medicine. 2007; pp.147:357.
- Zema F.J; Colesevelam hydrochloride and ezetimibe combination therapy provides effective lipid lowering in difficult to treat patients with hypercholesterolemia; American journal of Therapeutics;2005; 12(4);pp.306-310.
- Sembulingam K ,Sembulingam P, et.al ; Essentials of medical physiology, 4th edn. New Delhi 1999, 4th edn: pp.236-253.
- Davis S.N, Granner D.K; Insulin, oral hypoglycemic agent, and the pharmacology of endocrine pancreas. In Hardman, J.G Limbird, J.E Goodman and Gilmans: The pharmacology basis of therapeutic, McGraw Hill, New Delhi. 2001; 10th ed: pp.989-990 and 1679-1710.
- Zieve F.J, Kalin M.F; Schwartz S.L; Jones M.R; Bailey W.L; Results of the glucose lowering effect of Welchol study (GLOWS);A randomized, double-bind placebo controlled pilot study evaluating the effect of Colesevelam hydrochloride on glycemic control in subjects with type-2 diabetes. Clinical therapeutics; 2007;29(1), pp.74-83.
- Brufau G, et al. Altered bile salt metabolism in type 2 diabetes mellitus (T2DM). Abstract presented at the ADA 68th Scientific Sessions; San Francisco, CA (June 2008).
- Beysen C et al. Colesevelam HCl Improves Glucose Metabolism and Increases Glucagon-like Peptide 1 and Glucose-dependent Insulinotropic Polypeptide Concentrations in Type 2 Diabetes. Abstract presented at the 49th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria (September 29 – October 2, 2009).
- New Frontiers on Hyperlipidemia in Pharmaceutical Education
Abstract Views :252 |
PDF Views:2
Authors
Affiliations
1 Bharat Technology, Banitabla, Uluberia, Howrah, W.B., IN
1 Bharat Technology, Banitabla, Uluberia, Howrah, W.B., IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 4 (2010), Pagination: 257-260Abstract
The condition of hyperlipidemia can be described as high cholesterol in the blood (hypercholesterolemia), high triglycerides in the blood (hypertriglyceridemia) or it could be both. Hyperlipidemia is a major risk factor in the initiation and progression of atherosclerotic lesions, conditions such as coronary heart disease, ischemic cerebrovascular disease and peripheral vascular disease which leads high morbidity rate in developed countries. The present article gives different classes of anti-hyperlipidemics highlighting the pathophysiology of artherosclerosis, classification, side effects and therapeutic uses of antihyperlipidemics.Keywords
Hyperlipidemia, Cholesterol, Atherosclerotic Blood Vessel.References
- Devlin, T. (1995): Textbook of biochemistry with clinical correlations, New York, Wiley - Liss Inc, 3rd edition, pp. 376-381.
- Yan Feng, Xiumei Hong, Elissa Wilker, Zhiping Li, Wenbin Zhang, Delai Jin, Xue Liu, Tonghua Zang, Xiping Xu, and Xin Xu; Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases; Atherosclerosis. Feb 2008; 196(2) pp 590-597.
- Claudio Rigatto, Patrick Parfrey; Factors Governing Cardiovascular Risk In The Patient With A Failing Renal Transplant; Peritoneal Dialysis International, June 2001; Vol. 21 (3), pp 275.
- Olin B.R, Hebel S.K, Dombek C.E, Drug Facts and Comparisons. 2007 edition. pp-57.
- Simon C, Everitt H, Kendrick T. Oxford Handbook of General Practice. 2nd edn. Oxford: Oxford University Press, 2007: pp-324-325.
- Axel K. Duwe; Depressed Natural Killer and Lecithin-Induced Cell-Mediated Cytotoxicity in Cholesterol-Fed Guinea Pigs; journal of the national cancer institute; 1984; 72(2): pp-333-338.
- Peter Libby; Review article Inflammation in atherosclerosis; Nature, December 2002; 420, pp-868-874.
- Kumar A & Sharma A Kumar; Ayurvedic Management Of High Cholesterol; Ayurveda; December, 2009; 1(15); pp-23-26.
- Allain, C.C., Poon, L.S. and Chen, C.S. Enzymatic determination of total serum cholesterol, Clin Chem, 1974: 20, pp. 470-475.
- Murty, M.K.M. Surulivel. and Manavalan, R. (2006): "The effect of hippophae rhamnoidis L fruit juice and rhododendron arboreum flower juice mixture in rabbit model of hyperlipidaemia", pp. 1.
- Tripathi, K.D. (2003): Essentials of medical pharmacology, Jaypee brothers medical publishers (P) LTD, New Delhi, 5th edn., pp. 575.
- Inoue, M., Wu, C.Z. and Ogihara, Y. (1999): "Antihyperlipidemic action of Ogi-Keishi-Gomotsu-To-Ka-Kojin against cyclophosphamide-induced hyperlipidemia in rabbits", Biol Pharm Bull, pp. 486.
- Inoue, M. (2000): Shosaikoto "as a potential antiatherosclerotic agent", Drug News Perspect. pp. 407.
- Johnston, T.P. (2004): "The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis", J Cardiovasc Pharmacol, pp. 595.